Watch the presentation of this webinar here: https://bit.ly/3MJ4u9V Testing for presence of replication competent adenovirus (RCA) is a key component to ensure patient safety and a requirement for all biologicals manufactured using adenoviral vectors. For many adenoviral-based products, the RCA assay is a rate-limiting assay for lot release. Join this webinar to learn about a rapid RCA detection assay currently in development, which combines a 7-day culture assay with a highly sensitive molecular endpoint specific for RCA. The method can detect presence of as little as 1 RCA in adenoviral vector material at an approximate concentration of 5x107 - 2x108 vector particles (VP)/mL, making it a suitable method to meet regulatory requirements while accelerating your lot release timelines. In this webinar, you will learn about: • Regulatory framework for adenoviral vector products • Considerations for lot release testing of adenoviral-based therapies • Advantages of a rapid method for RCA testing on production lot material Presented by: Axel Fun, Ph.D., Principal Scientist Alberto Santana, MBA, Product Manager, Biologics Biosafety Testing